BioNeutra Global Corp (BGA) - Total Liabilities
Based on the latest financial reports, BioNeutra Global Corp (BGA) has total liabilities worth CA$21.81 Million CAD (≈ $15.77 Million USD) as of September 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore BioNeutra Global Corp cash conversion from operations to assess how effectively this company generates cash.
BioNeutra Global Corp - Total Liabilities Trend (2013–2023)
This chart illustrates how BioNeutra Global Corp's total liabilities have evolved over time, based on quarterly financial data. Check BGA cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
BioNeutra Global Corp Competitors by Total Liabilities
The table below lists competitors of BioNeutra Global Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Troubadour Resources Inc
V:TR
|
Canada | CA$325.75K |
|
Brave Bison Group PLC
LSE:BBSN
|
UK | GBX14.90 Million |
|
PHAXIAM Therapeutics S.A.
PA:PHXM
|
France | €23.66 Million |
|
Mastrad
PA:ALMAS
|
France | €3.00 Million |
|
Ten Lifestyle Group PLC
LSE:TENG
|
UK | GBX28.15 Million |
|
Satis Group S.A.
WAR:STS
|
Poland | zł274.74 Million |
|
Maven Income and Growth VCT 4 PLC
LSE:MAV4
|
UK | GBX398.00K |
|
Ristia Bintang Mahkotasejati
JK:RBMS
|
Indonesia | Rp291.12 Billion |
Liability Composition Analysis (2013–2023)
This chart breaks down BioNeutra Global Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of BioNeutra Global Corp.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.35 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.65 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.61 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BioNeutra Global Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BioNeutra Global Corp (2013–2023)
The table below shows the annual total liabilities of BioNeutra Global Corp from 2013 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | CA$21.96 Million ≈ $15.89 Million |
-6.70% |
| 2022-12-31 | CA$23.54 Million ≈ $17.03 Million |
+6.42% |
| 2021-12-31 | CA$22.12 Million ≈ $16.00 Million |
-3.74% |
| 2020-12-31 | CA$22.98 Million ≈ $16.62 Million |
-21.51% |
| 2019-12-31 | CA$29.27 Million ≈ $21.18 Million |
+33.49% |
| 2018-12-31 | CA$21.93 Million ≈ $15.86 Million |
+28.88% |
| 2017-12-31 | CA$17.01 Million ≈ $12.31 Million |
-18.26% |
| 2016-12-31 | CA$20.81 Million ≈ $15.06 Million |
+79.56% |
| 2015-12-31 | CA$11.59 Million ≈ $8.39 Million |
+263.80% |
| 2014-12-31 | CA$3.19 Million ≈ $2.30 Million |
-25.00% |
| 2013-12-31 | CA$4.25 Million ≈ $3.07 Million |
-- |
About BioNeutra Global Corp
BioNeutra Global Corporation engages in the research and development, production, and commercialization of food for nutraceutical, functional, and mainstream food and beverage products with a focus on oligosaccharides. The company offers isomalt oligosaccharide ingredients under the VitaFiber brand for human digestive health. It operates in Canada, the United States, Australia, New Zealand, Europ… Read more